Lexeo Therapeutics, Inc.
$6.53
▲
0.88%
2026-04-21 08:00:01
www.lexeotx.com
NGM: LXEO
Explore Lexeo Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$511.94 M
Current Price
$6.53
52W High / Low
$10.99 / $2.19
Stock P/E
—
Book Value
$3.38
Dividend Yield
—
ROCE
-85.23%
ROE
-55%
Face Value
—
EPS
$-1.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
59
Beta
2
Debt / Equity
3.2
Current Ratio
11.21
Quick Ratio
11.21
Forward P/E
-4.56
Price / Sales
—
Enterprise Value
$269.16 M
EV / EBITDA
-2.48
EV / Revenue
—
Rating
Strong Buy
Target Price
$19.64
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Capricor Therapeutics, Inc. | $34.21 | — | $2.04 B | — | -33.78% | -46.56% | $40.37 / $4.3 | $5.33 |
| 2. | Cyclerion Therapeutics, Inc. | $3 | — | $13.08 M | — | -40.99% | -39.34% | $8.48 / $1.03 | $2.38 |
| 3. | Relay Therapeutics, Inc. | $16.4 | — | $3 B | — | -50.82% | -41.12% | $17.32 / $2.53 | $3.26 |
| 4. | Vivani Medical, Inc. | $1.51 | — | $127.82 M | — | -84.04% | -1.6% | $1.92 / $0.92 | $0.21 |
| 5. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 6. | MBX Biosciences, Inc. | $33.78 | — | $1.6 B | — | -26.53% | -27.76% | $44.89 / $7.09 | $8.22 |
| 7. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -23.12 M | -21.65 M | -30.69 M | -33.8 M | -27.38 M | — |
| Net Profit | -20.92 M | -20.28 M | -26.1 M | -32.66 M | -25.92 M | — |
| EPS in Rs | -0.28 | -0.27 | -0.35 | -0.44 | -0.35 | -0.89 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.65 M |
| Operating Profit | -109.26 M | -105.77 M | -68.51 M | -60.51 M |
| Net Profit | -99.96 M | -98.33 M | -66.39 M | -59.28 M |
| EPS in Rs | -1.35 | -1.33 | -0.9 | -0.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 268.69 M | 146.94 M | 139.81 M | 97.08 M |
| Total Liabilities | 22.02 M | 30.1 M | 26.27 M | 210.03 M |
| Equity | 246.67 M | 116.84 M | 113.53 M | -112.95 M |
| Current Assets | 188.39 M | 126.12 M | 124.29 M | 80.05 M |
| Current Liabilities | 16.81 M | 22.85 M | 17.24 M | 14.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -98.56 M | -81.15 M | -59.5 M | -54.56 M |
| Investing CF | -90.25 M | -94.08 M | -0.17 M | -0.9 M |
| Financing CF | 216.79 M | 88.78 M | 103.79 M | 0.19 M |
| Free CF | -98.96 M | -81.63 M | -59.66 M | -55.46 M |
| Capex | -0.4 M | -0.48 M | -0.17 M | -0.9 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -48.11% | -12.01% | — | — |
| Profit Margin % | — | — | -9063.76% | — |
| Operating Margin % | — | — | -9252.14% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -8874.77% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.